Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average rating of “Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $8.8333.

A number of equities analysts recently issued reports on AQST shares. Piper Sandler upped their price objective on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Zacks Research upgraded shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. JMP Securities increased their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a research note on Thursday, October 9th. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Aquestive Therapeutics Stock Performance

AQST opened at $3.24 on Friday. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $7.55. The firm has a market cap of $395.28 million, a P/E ratio of -4.56 and a beta of 1.66. The business’s fifty day moving average is $5.51 and its 200-day moving average is $5.24.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. On average, research analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets raised its stake in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the last quarter. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics in the second quarter valued at approximately $33,000. USAdvisors Wealth Management LLC purchased a new position in shares of Aquestive Therapeutics during the second quarter valued at approximately $33,000. Finally, First National Bank & Trust Co. of Newtown bought a new stake in Aquestive Therapeutics during the second quarter worth $50,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.